Silo Pharma Closes Private Placement, Expects About $815,000 in Net Proceeds
Bitget2026/11/06 22:08- Silo Pharma closed a private placement on Nov. 6, 2026, with expected net proceeds of approximately $815,000.
- Purchase agreements dated Nov. 5, 2026, covered 136,005 common shares at $1.50 per share.
- The placement also included pre-funded warrants to purchase 430,661 common shares at $1.4999 per warrant.
- The pre-funded warrants are immediately exercisable at $0.0001 per share.
- Net proceeds are intended for working capital and general corporate purposes.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.


Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
